Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.
Mendoza N, Ramírez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P, Nieto V, Otero B, Sánchez-Méndez S, de Frutos VÁ, Andraca L, Barriga P, Benítez Z, Bombas T, Cancelo MJ, Cano A, Branco CC, Correa M, Doval JL, Fasero M, Fiol G, Garello NC, Genazzani AR, Gómez AI, Gómez MÁ, González S, Goulis DG, Guinot M, Hernández LR, Herrero S, Iglesias E, Jurado AR, Lete I, Lubián D, Martínez M, Nieto A, Nieto L, Palacios S, Pedreira M, Pérez-Campos E, Plá MJ, Presa J, Quereda F, Ribes M, Romero P, Roca B, Sánchez-Capilla A, Sánchez-Borrego R, Santaballa A, Santamaría A, Simoncini T, Tinahones F, Calaf J. Mendoza N, et al. Among authors: ramirez i. Maturitas. 2022 Dec;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. Epub 2022 Aug 30. Maturitas. 2022. PMID: 36081216
Can a meta-analysis that included articles with high heterogeneity appropriately evaluate the risk of venous thromboembolism in users of combined hormonal contraceptives containing drospirenone or desogestrel? A reply to Rosa et al.
Martínez F, Latorre K, Ramírez I, Pérez-Campos E, Lete I. Martínez F, et al. Among authors: ramirez i. Eur J Contracept Reprod Health Care. 2013 Apr;18(2):139-42. doi: 10.3109/13625187.2013.780593. Eur J Contracept Reprod Health Care. 2013. PMID: 23496253 No abstract available.
Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia.
Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N, Otero B, Sánchez S, Cancelo MJ, Páramo JA, Cano A. Ramírez I, et al. Maturitas. 2020 Jul;137:57-62. doi: 10.1016/j.maturitas.2020.04.019. Epub 2020 May 6. Maturitas. 2020. PMID: 32498938 Free PMC article.
The thromboembolic risk in covid-19 women under hormonal treatment group.
Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N, Otero B, Sánchez S, Cancelo MJ, Páramo JA, Cano A. Ramírez I, et al. Maturitas. 2020 Aug;138:78-79. doi: 10.1016/j.maturitas.2020.05.021. Epub 2020 Jun 18. Maturitas. 2020. PMID: 32565010 Free PMC article. No abstract available.
Response to "Should estrogen be used in the co-treatment of COVID-19 patients?".
Cano A, Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Otero B, Sánchez S, Cancelo MJ, Páramo JA, Mendoza N. Cano A, et al. Among authors: ramirez i. Maturitas. 2020 Oct;140:81-82. doi: 10.1016/j.maturitas.2020.06.014. Epub 2020 Jul 31. Maturitas. 2020. PMID: 32747134 Free PMC article. No abstract available.
378 results